Easton DF, Ford D, Bishop DT.for the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation
carriers. Am J Hum Genet.1995;56:265-271.
Ford D, Easton DF, Stratton M.
et al. for the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet.1998;62:676-689.
Broet P, de la Rochefordiere A, Scholl SM.
et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol.1995;13:1578-1583.
Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on
prognosis. J Clin Oncol.1993;11:1545-1552.
Rosen PP, Groshen S, Kinne DW, Hellman S. Contralateral breast carcinoma: an assessment of risk and prognosis
in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery.1989;106:904-910.
Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol.1991;9:1650-1661.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin.1998;48:6-29. [published corrections appear in CA Cancer J Clin. 1998;48:192 and CA Cancer J Clin. 1998;48:329].
Hartmann LC, Schaid DJ, Woods JE.
et al. Efficacy of bilateral prophylactic mastectomy in women with a family
history of breast cancer. N Engl J Med.1999;340:77-84.
Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr.1995;17:33-35.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet.1998;351:1451-1467.
Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis: effects of prophylactic mastectomy and oophorectomy
on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med.1997;336:1465-1471.
Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive
patients. J Clin Oncol.1998;16:979-985.
Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making.1998;18:365-375.
Ventura SJ, Anderson RN, Martin JA, Smith BL. Births and deaths: preliminary data for 1997. Natl Vital Stat Rep.1998;47:1-41.
Verhoog LC, Brekelmans CT, Seynaeve C.
et al. Survival and tumour characteristics of breast-cancer patients with
germline mutations of BRCA1. Lancet.1998;351:316-321.
Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer
patients: a population-based study from southern Sweden. J Clin Oncol.1998;16:397-404.
Lee JS, Wacholder S, Struewing JP.
et al. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst.1999;91:259-263.
Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised
Chu KC, Tarone RE, Kessler LG.
et al. Recent trends in U.S. breast cancer incidence, survival, and mortality
rates. J Natl Cancer Inst.1996;88:1571-1579.
Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer.1998;82:1197-1207.
Smart CR, Byrne C, Smith RA.
et al. Twenty-year follow-up of the breast cancers diagnosed during the Breast
Cancer Detection Demonstration Project. CA Cancer J Clin.1997;47:134-149.
Robson M, Gilewski T, Haas B.
et al. BRCA-associated breast cancer in young women. J Clin Oncol.1998;16:1642-1649.
Fodor FH, Weston A, Bleiweiss IJ.
et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish
breast cancer patients. Am J Hum Genet.1998;63:45-51.
Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet.1996;14:185-187.
Thorlacius S, Struewing JP, Hartge P.
et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet.1998;352:1337-1339.
Struewing JP, Hartge P, Wacholder S.
et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med.1997;336:1401-1408.
Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations
in breast cancer and ovarian cancer: results from three U.S. population-based
case-control studies of ovarian cancer. Am J Hum Genet.1997;60:496-504.
Burke W, Daly M, Garber J.
et al. for the Cancer Genetics Studies Consortium. Recommendations for follow-up care of individuals with an inherited
predisposition to cancer, II: BRCA1 and BRCA2. JAMA.1997;277:997-1003.
Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers
in carriers of BRCA1 or BRCA2
mutations and sporadic cases. Lancet.1997;349:1505-1510.
DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell Jr JR. Transvaginal sonography as a screening method for the detection of
early ovarian cancer. Gynecol Oncol.1997;65:408-414.
US Surveillance and Epidemiology End Results Program. SEER Public Use Data 1973-1994. Bethesda, Md: National Cancer Institute, Cancer Statistics Branch;
Ries LA. Ovarian cancer: survival and treatment differences by age. Cancer.1993;71(2 suppl):524-529.
Rubin SC, Benjamin I, Behbakht K.
et al. Clinical and pathological features of ovarian cancer in women with
germ-line mutations of BRCA1. N Engl J Med.1996;335:1413-1416.
Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized
clinical trial comparing total mastectomy with lumpectomy with or without
irradiation in the treatment of breast cancer. N Engl J Med.1995;333:1456-1461.
Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC, Mok SC. BRCA1 gene mutations in women with papillary
serous carcinoma of the peritoneum. Obstet Gynecol.1998;92(4 pt 1):596-600.
Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital,
London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal
women with pathological stage II breast carcinoma: the Scottish trial. Lancet.1993;341:1293-1298.
Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised
Rivkin SE, Green S, O'Sullivan J.
et al. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal,
node-positive, and estrogen receptor–positive breast cancer patients:
a Southwest Oncology Group study. J Clin Oncol.1996;14:46-51.
Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast cancer risk associated with gynecologic surgery and indications
for such surgery. Int J Cancer.1997;70:150-154.
Rebbeck TR, Levin AM, Eisen A.
et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst.1999;91:1475-1479.
Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med.1987;316:1105-1110.
DiSaia PJ, Grosen EA, Odicino F.
et al. Replacement therapy for breast cancer survivors: a pilot study. Cancer.1995;76(10 suppl):2075-2078.
Stampfer MJ, Colditz GA, Willett WC.
et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year
follow-up from the Nurses' Health Study. N Engl J Med.1991;325:756-762.
van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet.1996;347:714-718.
Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol.1998;8:229-235.
Colditz GA. Estrogen replacement therapy for breast cancer patients. Oncology (Huntingt).1997;11:1491-1494.
Lerman C, Narod S, Schulman K.
et al. BRCA1 testing in families with hereditary
breast-ovarian cancer: a prospective study of patient decision making and
Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with
node-negative breast cancer: a decision-analysis model. N Engl J Med.1991;324:160-168.
Wright JC, Weinstein MC. Gains in life expectancy from medical interventions—standardizing
data on outcomes. N Engl J Med.1998;339:380-386.
Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies. JAMA.1995;274:881-884. [published correction appears in JAMA. 1996;275:112].
Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy from various coronary heart disease
risk factor modifications. Circulation.1991;83:1194-1201. [published correction appears in Circulation. 1991;84:2610].
Fisher B, Costantino JP, Wickerham DL.
et al. Tamoxifen for prevention of breast cancer: report of the National Surgical
Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst.1998;90:1371-1388.
Johannsson OT, Idvall I, Anderson C.
et al. Tumour biological features of BRCA1-induced
breast and ovarian cancer. Eur J Cancer.1997;33:362-371.
Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med.1999;130:431-439.
Narod SA, Risch H, Moslehi R.
et al. for the Hereditary Ovarian Cancer Clinical Study Group. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med.1998;339:424-428.